STARTER-NET rand PhIII of 1:1 everolimus + lanreotide vs evero alone in #1L G1/2 adv #GEP-NET ➡️ sig improved median PFS (29.7 mos vs 11.5 mos), higher ORR (23% vs 8.3%), more G3 tox w/combo. No sig diff in OS. Why evero alone as control arm?

@OncoAlert @LACNETS @NANETS1
#1L #GEP